Scarica l'app Stockscreener
2.14
8.97%
-0.20
Clearmind Medicine Inc Borsa (CMND) Ultime notizie
CMND Stock Slides As Traders Gauge Cash Runway And Volatility - StocksToTrade
Clearmind Medicine Reports Successful Formulation Feasibility for Intranasal MEAI Development Program for Alcohol Use Disorder - Quiver Quantitative
symbol__ Stock Quote Price and Forecast - CNN
Clearmind Medicine receives U.S. patent for binge behavior treatment - Investing.com UK
Clearmind Medicine receives U.S. patent for binge behavior treatment By Investing.com - Investing.com Australia
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength - The Manila Times
Clearmind Medicine(CMND) Stock Options Chain | Quotes & News - Moomoo
Clearmind Medicine Company Profile & Introduction - Moomoo
Price to earnings forward of Clearmind Medicine Inc. – MUN:CWY0 - TradingView
Price to earnings forward of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
Enterprise value to revenue forward of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
Price to sales forward of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
Price to book forward of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
Clearmind Medicine Reaches Major Milestone, Completing Part a Treatment in FDA-Regulated Phase I/II Trial - marketscreener.com
Clearmind Medicine Inc (CMND) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Clearmind completes treatment phase of alcohol disorder trial - Investing.com UK
Clearmind Medicine (CMND) Completes Phase I/II Trial for Alcohol Use Disorder - GuruFocus
Clearmind completes treatment phase of alcohol disorder trial By Investing.com - Investing.com South Africa
Form 6K Clearmind Medicine Inc For: 22 June By Investing.com - Investing.com Nigeria
Clearmind Medicine Completes Treatment for All Participants in Part A of Phase I/II Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial - The Manila Times
Clearmind Medicine (Nasdaq: CMND) hits CMND-100 Phase I/II milestone - Stock Titan
Insider Selling: Financial Hrt Sells Shares of Clearmind Medicine Inc (CMND) - GuruFocus
HRT Financial LP trims Clearmind Medicine (CMND) stake with 22,139-share sale - Stock Titan
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators - The Manila Times
Clearmind Medicine (NASDAQ: CMND) secures U.S. patent for MEAI binge behavior regulators - Stock Titan
Clearmind Medicine Inc Share PriceCMND, RNS News, Articles, Quotes, & Charts (NASDAQ:CMND) - Proactive financial news
Insider Sell: Financial Hrt Reduces Stake in Clearmind Medicine Inc (CMND) - GuruFocus
Clearmind Medicine Inc (CMND) Institutional Confidence - TradingKey
Clearmind Medicine Inc (CMND) Valuation: PE, PB & Fair Value Analysis - TradingKey
Clearmind Medicine (CMND) holder HRT Financial LP sells 3,183 shares - Stock Titan
Clearmind Medicine Inc (CMND) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Clearmind Medicine Inc (CMND) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Clearmind Medicine Inc (CMND) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Clearmind Medicine Inc (CMND) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Clearmind Medicine Inc (CMND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Clearmind Medicine Inc (CMND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Clearmind completes dosing for phase I/II alcohol disorder trial By Investing.com - Investing.com South Africa
Clearmind Medicine finishes dosing 24 trial participants - grafa.com
Clearmind completes dosing for phase I/II alcohol disorder trial - Investing.com UK
HRT Financial LP trims Clearmind Medicine (CMND) stake with 2,102-share sale - Stock Titan
Clearmind Medicine Completes Dosing For Part A Of Its Of FDA-Regulated Phase I/Ii Clinical Trial - TradingView
Clearmind Medicine Inc. Successfully Completes Dosing in Phase I/II Clinical Trial for CMND-100 to Treat Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine (NASDAQ: CMND) finishes Part A dosing in CMND-100 Alcohol Use Disorder trial - Stock Titan
Experimental alcohol addiction drug completes first-stage testing - Stock Titan
Clearmind Medicine | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
Clearmind Medicine (NASDAQ: CMND) flags going concern risk after $5.9M loss - Stock Titan
Cash per share of Clearmind Medicine Inc. – FWB:CWY0 - TradingView
Tangible book value per share of Clearmind Medicine Inc. – FWB:CWY0 - TradingView
1.16%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):